Induction of humoral immune response against PfMSP-119 and PvMSP-119 using gold nanoparticles along with alum

Parween, Shaheena; Gupta, Puneet Kumar; Chauhan, Virander S.

doi:10.1016/j.vaccine.2011.01.014

Cited by 45 publications

(32 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…falciparum chimeric line that expresses P. falciparum MSP-1 19 19 induced specific antibody responses and T-cell responses with six different adjuvants in immunized mice, and high levels of immunoglobulin G1 (IgG1), IL-4, interleukin-5 (IL-5) and IFN-γ were detected. Parween et al (46) showed that the immunogenicity of recombinant P. falciparum MSP-1 19 and P. vivax MSP-1 19 was strongly enhanced when the recombinant proteins were coated on Gold Nanoparticles formulated with alum. The raised anti-PfMSP-1 19 antibodies could inhibit an in vitro merozoite invasion.…”

Section: Immunogenicity Of Msp-1 In Rodent Modelsmentioning

confidence: 99%

Immunogenicity of the Merozoite Surface Protein-1 (Msp-1) of Human Plasmodium Sp.

Yl¹,

Fw²,

My³

2015

JUMMEC

View full text Add to dashboard Cite

Malaria is a major cause of mortality and morbidity globally. Great efforts have been made in the prevention and the elimination of malaria, especially in controlling the malaria vector, the mosquito. Another promising approach would be the development of malaria vaccines. Malaria vaccine studies can be focused on the pre-erythrocytic-stage antigens and the blood-stage antigens, and on the transmission blocking agents targeting the malaria gametocytes. The blood-stage antigens are the leading candidates in malaria vaccine development, as the blood-stage parasites are responsible for causing symptomatic malaria. Human acquired immunity largely targets on blood-stage antigens. This review focuses on one of the most extensively studied blood-stage antigen, the merozoite surface protein-1 (MSP-1), specifically on its evaluation and immunogenicity in rodents and primate models, and its safety and immunogenicity in human clinical trials.

show abstract

Section: Immunogenicity Of Msp-1 In Rodent Modelsmentioning

confidence: 99%

Immunogenicity of the Merozoite Surface Protein-1 (Msp-1) of Human Plasmodium Sp.

Yl¹,

Fw²,

My³

2015

JUMMEC

View full text Add to dashboard Cite

show abstract

“…In the absence of this technique, so by passive diffusion, the immunological effects were not so interesting [140]. Other recent studies show that the use of gold nanoparticles along with alum can enhance the immune response against PfMSP-119 and PvMSP-119 [141].…”

Section: Nondegradable Polymeric Nanoparticlesmentioning

confidence: 99%

Genetic toxicology and preliminaryin vivostudies of nitric oxide donor tocopherol analogs as potential new class of antiatherogenic agents

Cabrera

López

Gómez

et al. 2011

Drug and Chemical Toxicology

View full text Add to dashboard Cite

In the last decades, significant progress in research and clinics has been made to offer possible innovative therapeutics for the management of allergic diseases. However, current allergen immunotherapy shows limitations concerning the long-term efficacy and safety due to local side effects and risk of anaphylaxis. Thus, effective and safe vaccines with reduced dose of allergen have been developed using adjuvants. Nevertheless, the use of adjuvants still has several disadvantages, which limits its use in human vaccines. In this context, several novel adjuvants for allergen immunotherapy are currently being investigated and developed. Currently, nanoparticles-based allergen-delivery systems have received much interest as potential adjuvants for allergen immunotherapy. It has been demonstrated that the incorporation of allergens into a delivery system plays an important role in the efficacy of allergy vaccines. Several nanoparticles-based delivery systems have been described, including biodegradable and nondegradable polymeric carriers. Therefore, this paper provides an overview of the current adjuvants used for allergen immunotherapy. Furthermore, nanoparticles-based allergen-delivery systems are focused as a novel and promising strategy for allergy vaccines.

show abstract

“…No staining was observed with mouse pre-immune serum, while surface staining was observed with MSP-119[17] (Fig. 2A).…”

mentioning

confidence: 95%

“…As a control, mature schizonts were also stained with mouse pre-immune serum at the same dilution (1:150), and rabbit serum against merozoite Cellular localization of PfAEP was investigated by co-localization with apical organelle proteins in mature schizonts by immunofluoresence assay as described earlier [15]. PfAEP (mouse/rabbit serum 1:100/1:150) was co-stained with micronemal protein EBA-175 and AMA-1 [13], rhoptry bulb protein PfTRAMP [14], rhoptry neck proteins apical asparagine rich protein (PfAARP) and apical rhoptry neck protein (PfARNP) [13,9] and merozoite surface marker MSP-119 [17]. PfAEP showed staining in apical manner, distinct from nuclear stain DAPI but analogous to EBA -175 and PfTRAMP.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Identification and localization of a Novel Invasin of Plasmodium falciparum

Hans

Relan

Dubey

et al. 2015

Molecular and Biochemical Parasitology

View full text Add to dashboard Cite

Induction of humoral immune response against PfMSP-119 and PvMSP-119 using gold nanoparticles along with alum

Cited by 45 publications

References 58 publications

Immunogenicity of the Merozoite Surface Protein-1 (Msp-1) of Human Plasmodium Sp.

Immunogenicity of the Merozoite Surface Protein-1 (Msp-1) of Human Plasmodium Sp.

Genetic toxicology and preliminaryin vivostudies of nitric oxide donor tocopherol analogs as potential new class of antiatherogenic agents

Identification and localization of a Novel Invasin of Plasmodium falciparum

Contact Info

Product

Resources

About